Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Abstract: Provided is a substance capable of effectively suppressing cancer metastasis or a pharmaceutical composition that effectively acts on an inflammatory disease. The pharmaceutical composition is a pharmaceutical composition containing, as an active ingredient, an antibody or an antibody fragment thereof having antigen-binding activity for an S100A8/A9 heterodimer, and blocks interaction between S100A8/A9 and a group of receptors therefor, to thereby strongly suppress cancer metastasis both in vitro and in vivo, or alleviate inflammation. That is, the anti-S100A8/A9 antibody or the antibody fragment thereof can strongly suppress cancer metastasis or alleviate inflammation, by virtue of its blocking action on the interaction between S100A8/A9 and the group of receptors therefor.

Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.

Abstract: An infrared radiation device includes a body including a heat generating part and first and second metamaterial structures that are capable of radiating infrared rays having a peak wavelength of a non-Planck distribution upon receipt of thermal energy from the heat generating part. The first metamaterial structure is disposed on a first surface side of the heat generating part, and the second metamaterial structure is disposed on a second surface side opposite to the first surface side of the heat generating part.

Abstract: A method, a program, and a method determining hypermutated type cancer with higher accuracy than before is provided.

Abstract: The aminosilane-modified colloidal silica dispersion contains colloidal silica particles having surfaces to which there are bound a first silyl group represented by the following formula (1): R1aSi(OR2)3-aO— and a second silyl group represented by the following formula (2): R3bSi(OR4)3-bO— and, as a dispersion medium, a mixed solvent formed of a polar solvent S1 having a dielectric constant at 20° C. of 15 or higher and lower than 60 and a non-polar solvent S2 having a dielectric constant at 20° C. of 1 or higher and lower than 15, at a mass ratio (S1/S2) of 0.3 to 6.

Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein a fourth amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, (a) having a QXXXGX(W/F) motif, and a QXXXX(G/A)X(F/W/Y) motif on the N-terminal side, and a QXXXGX(F/W/Y) motif, and a QXXXGXW motif and a QXXXGX(F/W) motif on the C-terminal side, and not having a QXXXGXW motif at a position separated by 170 amino acid residues or more on the C-terminal side, with respect to the DXDD motif, (b) having 40% or more identity with the amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 13, (c) exhibiting ambrein production activity using squalene as a substrate.

Abstract: An object of the present invention is to provide a method for preparing ambrein, which can easily and efficiently obtain the ambrein. The object can be solved by a mutated tetraprenyl-?-curcumene cyclase wherein (1) a 4th amino acid residue of a DXDD motif, aspartic acid, is substituted with an amino acid other than aspartic acid, and (2) an amino acid adjacent to the N-terminus of a (A/S/G)RX(H/N)XXP motif is substituted with an amino acid other than tyrosine, or a 4th amino acid of the GXGX(G/A/P) motif is substituted with an amino acid other than leucine.

Abstract: Provided is a pseudo visceral model having a specific texture. A model of viscera, tissues, or organs comprising a foam layer containing a hydrogel.

Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.

Abstract: Disclosed is a peptide of the following (a) or (b): (a) a peptide containing an amino acid sequence including a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4; and (b) a peptide containing an amino acid sequence including a sequence having at least 60% identity with a sequence set forth in any one of SEQ ID NOS: 1, 2, 3, and 4, the peptide having highly-shifted accumulation to pancreatic cancer cells and tissues.

Abstract: An aquaporin 4 function promotor contains a compound represented by Formula (1) or (2) or a pharmaceutically acceptable salt thereof, as an active ingredient. (In the formula, n11 represents an integer of 1 to 10, and R21 represents one selected from the group consisting of an alkyl group having 1 to 10 carbon atoms, an alicyclic heterocyclic group, an aromatic hydrocarbon group, and an aromatic heterocyclic group.

Abstract: A method for preparing a compact of resin compound comprising the following steps (a) to (c): (a) a preparation step of mounting a sheet-shaped or block-shaped compact of resin compound including a resin composition, which contains a filler having magnetic anisotropy and is solidified by curing or by being advanced to a B-stage, on a transportation unit which is movable in the horizontal direction, and covering at least a top surface of the compact of resin compound with a cover material; (b) a step of applying a magnetic field to the compact of resin compound obtained in the step (a) with a bulk superconductor magnet having a central magnetic flux density of 1 T or more; and (c) a step of moving the compact of resin compound in the horizontal direction and scanning it while applying vibrations to the compact of resin compound mounted on a region of a central part of the bulk superconductor magnet under application of a magnetic field.

Abstract: The present invention includes cilastatin or a pharmaceutically acceptable salt thereof as an active component and a suppressant for renal impairment or inner ear disorders, induced via megalin by at least one megalin ligand which is selected from the group consisting of polymyxins, aminoglycoside antibiotics, glycopeptide antibiotics, cisplatin, and pharmaceutically acceptable salts thereof.

Abstract: An infrared heater includes a heater body and a casing. The heater body includes a heating element and a metamaterial structure capable of emitting infrared radiation having a peak wavelength of a non-Planck distribution when thermal energy is supplied from the heating element. The casing has an interior space in which the heater body is disposed and whose pressure is reducible. In addition, the casing includes an infrared radiation transmitting portion capable of transmitting the infrared radiation emitted by the metamaterial structure to an outside of the casing.

Abstract: A method for producing hydrogen of the present invention includes thermally reducing a reaction medium in which CeO2 is doped with a metal other than Ce and bringing the thermally reduced reaction medium into contact with water to oxidize the reaction medium and to generate the hydrogen. When a reaction temperature in the thermally reducing the reaction medium is defined as T1 [° C.] and a reaction temperature in the bringing the thermally reduced reaction medium into contact with the water is defined as T2 [° C.], a relation of T1?T2?150 is satisfied. It is preferred that a series of processes including the thermally reducing the reaction medium and the bringing the thermally reduced reaction medium into contact with the water is repeated.

Abstract: The present invention provides a method for producing a cell culture for promoting angiogenesis or axon outgrowth, particularly for the treatment of a cerebrovascular disease, an ischemic cardiac disease or traumatic brain injury and spinal cord injury, which comprises culturing a cell population containing microglia and/or monocytes under conditions of low oxygen concentration and/or low sugar concentration to produce the culture, a cell preparation obtained by the method, and a method for treating a cerebrovascular disease, an ischemic cardiac disease or traumatic cerebrospinal neuropathy by using the cell preparation.

Abstract: The present invention provides an agent or pharmaceutical composition for eliminating senescent cells, comprising an SGLT2 inhibitor.

Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.

Abstract: A heat receiver, a reactor, and a heater utilize the heat of concentrated solar light for thermal decomposition and/or chemical reaction of coals, etc. The heat receiver includes: a side portion forming a substantially cylindrical side surface; a substantially circular bottom portion connected to the lower edge of the side portion; and a ceiling connected to the upper edge of the side portion. A substantially circular aperture is formed in the center of the ceiling. The heat receiver has a substantially cylindrical cavity and the opening portion is open. When the cavity has a diameter of D and a length of L, and the aperture has a diameter of d, d=D/2 or less and L=2D or more. Concentrated solar light entering the heat receiver is to be contained in the heat receiver to effectively utilize the solar light.